Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Abstract Globally, cardiovascular diseases (CVDs) account for around one-third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon-like peptide-1 (GLP-1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all-cause mortality. Tirzepatide is a once-weekly, dual glucose-dependent […]
Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment
Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development. The decision is based on promising results from two early-phase clinical trials: one for a once-weekly subcutaneous formulation and another […]
LifeMD: An Overlooked GLP-1 Beneficiary
Post Content
These are the top 10 emerging technologies of 2025, according to the World Economic Forum
Breakthroughs happen all the time in the tech world, but only a select few manage to make a lasting impact. Predicting which innovations will shape the future is always a challenge. On Tuesday, the World Economic Forum (WEF) released its list of the top 10 emerging technologies of 2025, highlighting those expected to influence global […]
CagriSema: Weight Loss in Overweight or Obese Adults
This document details a Phase 3a, 68-week, multicenter, double-blind, placebo-controlled, and active-controlled clinical trial (REDEFINE 1) investigating the efficacy and safety of cagrilintide–semaglutide (CagriSema) for weight loss in adults who are overweight or obese. The study randomized over 3400 participants into groups receiving the combination therapy, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle interventions. Results demonstrated significant and clinically relevant body-weight […]
GLP-1 Agonists: Uses, Mechanism, and Side Effects
https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists The provided text from the Cleveland Clinic offers a comprehensive overview of GLP-1 agonists, a class of medications primarily used to manage Type 2 diabetes and obesity. It explains how these injectable drugs mimic a natural hormone to regulate blood sugar, slow digestion, and increase feelings of fullness, leading to potential weight loss. The source lists various approved GLP-1 agonists and their typical administration frequencies, […]
‘Ozempic Penis’: Males Are Reporting a Surprising New GLP-1 Side Effect
A growing number of males on Reddit are claiming that GLP-1 drugs have increased their penis size. Kupicoo/Getty Images Male Reddit users are reporting what they call “Ozempic penis,” with some claiming penile growth of up to 1.5 inches. Experts say, however, that Ozempic penis is not a true side effect of GLP-1 drugs. Instead, […]
Studies exploring muscle loss from GLP-1 drugs
GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat, experts say.
Semaglutide Shows Benefits for PAD Across T2D Subgroups
A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 diabetes, but more research is needed in those without diabetes. Medscape Medical News
Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs – Gizmodo
Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs Gizmodo Hims & Hers stock plunges after Novo Nordisk ends Wegovy direct sales deal Yahoo Finance HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law Business Wire Novo Nordisk ends collaboration with […]